Cell Based Assays Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028F, Segmented By Products & Services (Reagents, Assay Kits, Microplates, Probes & Labels, Cell Lines, Others), By Application (Clinical Research, Drug Discovery & Development, Others), By End User (Biotechnology & Pharmaceutical Companies, Academic & Research Institutions, Contract Research Organizations), By Region and Competition

The Global Cell-Based Assays Market is anticipated to witness an impressive growth during the forecast period. This can be ascribed to the growing demand for novel drugs for treating chronic diseases. Use of therapeutic drugs during various disease outbreaks, along with the growing number of research activities are two significant factors responsible for the growth of global cell-based assays market. Rising government expenditure in healthcare sector and the rising need for toxicity screening in drugs are expected to drive the market growth across different parts of the globe. Additionally, growing demand for efficient treatment for rare diseases is further expected to increase the demand for cell-based assays, thereby fuelling the market growth through 2028. Besides, growing awareness on the advantages of using new treatment along with the increasing demand to reduce the costs associated with drug discovery across the globe, are further expected to support the cell-based assays market during the forecast period. For instance, in November 2021, Menarini Silicon Biosystems, launched its CELLSEARCH, a laboratory-developed test to aid the enumeration of multiple myeloma cells using a blood sample. 

One of the major advantages of cell-based assays is their ability to provide more physiologically relevant data compared to traditional biochemical assays. In traditional biochemical assays, the activity of a compound is measured in vitro using isolated enzymes or proteins. However, this approach does not take into account the complexity of the cellular environment, which can have a significant impact on the activity of a compound. Cell-based assays, on the other hand, provide a more realistic representation of the in vivo environment and can better predict the activity of a compound in vivo. Cell-based assays have a wide range of applications in drug discovery, toxicology, and basic research. In drug discovery, cell-based assays are used to screen large libraries of compounds for their ability to modulate specific cellular pathways or to inhibit the growth of cancer cells. In toxicology, cell-based assays are used to evaluate the potential toxicity of compounds and to identify compounds that may cause adverse effects. In basic research, cell-based assays are used to study cellular signaling pathways, protein-protein interactions, and gene expression. Another advantage of cell-based assays is their ability to provide a functional readout of the activity of a compound. In traditional biochemical assays, the activity of a compound is measured using indirect methods such as enzyme activity assays or binding assays. In contrast, cell-based assays provide a direct measure of the activity of a compound in a cellular context. Despite their advantages, cell-based assays also pose several challenges.

One of the major challenges is the variability in the behavior of cells in culture. Cells can exhibit significant variability in their growth rate, response to stimuli, and other properties. This variability can make it difficult to interpret the results of cell-based assays and to compare the activity of compounds across different assays. Another challenge of cell-based assays is their cost and complexity. Cell-based assays require specialized equipment, reagents, and expertise, which can be costly and time-consuming to develop and maintain. As cell-based assays rely on living cells, there can be a significant degree of variability in cell behavior, including growth rates, responses to stimuli, and other properties. This variability can make it difficult to interpret the results of cell-based assays and can lead to inconsistent outcomes. Ensuring the reproducibility of cell-based assays can be challenging due to variability in cell behavior and the complex nature of the assays. Standardizing assay protocols and reagents can help to improve the reproducibility of these assays and reduce variability, but this requires significant effort and collaboration among researchers and assay developers. The use of living cells in assays raises ethical and regulatory concerns, particularly when it comes to the use of stem cells and other sensitive cell types. Regulations surrounding the use of cell-based assays can vary by region and can impact the development and adoption of these technologies.

Growing Demand for Cell Based Assays Will Propel the Market Growth

Increasing demand for identification and optimization procedures for the drug development is a major factor which will boost the market growth during the forecast period. Growing adoption by pharmaceutical and biotechnology firms is another important factor driving the growth for this market. Furthermore, the increasing risk of disease outbreaks like swine flu, COVID-19 and growing rate of research activities are also expected to fuel the market growth over the years. During September 28, 2020–May 22, 2021, in the United States, 1,675 (0.2%) of 818,939 respiratory specimens tested by U.S. clinical laboratories were positive for influenza virus. The low labour and raw material costs along with more and more CRO companies providing drug discovery services, are expected to create a lucrative growth during the forecast period. Increasing growth in the drug discovery projects and rising adoption of strategic approaches, like collaboration with different companies for developing new drugs, will further propel the growth of the market over the years. The rising demand for biopharmaceuticals and personalized medicine has led to the development of cell-based assays for drug discovery, toxicity testing, and quality control of biologics. The increasing prevalence of chronic diseases such as cancer, cardiovascular diseases, and neurological disorders has led to the development of cell-based assays for early diagnosis, drug discovery, and disease modeling. The development of advanced technologies such as high-content screening (HCS), 3D cell culture, and microfluidics has revolutionized cell-based assays, making them more efficient and effective. CRISPR-Cas9 technology is a gene-editing tool that has revolutionized the field of cell-based assays. This technology allows researchers to create genetically modified cell lines that can be used in a range of assays, including drug screening and toxicology. The use of CRISPR-Cas9 technology has also facilitated the development of more complex cell-based assays, such as those using organoids. Single-cell assays are becoming increasingly popular as they allow researchers to study the behavior of individual cells in greater detail. These assays can be used to investigate cell heterogeneity and to identify rare cell populations that may play a role in disease. Single-cell assays can also be used to evaluate the effects of compounds on individual cells, providing a more detailed understanding of drug action.

Increasing Number of Drug Discovery Activities Will Fuel the Market Growth

Increasing prevalence of lifestyle disorders like arthritis, diabetes, epilepsy, cancer, cardiovascular diseases, etc., will enhance the growth of the cell-based assay market. Government organizations are investing in research and development sector for developing new drug for the diagnosis of chronic diseases such as cancer, diabetes, auto immune disorders, which is expected to create a lucrative growth during the forecast period. Rising demand for novel drug across the world for the treatment of pandemic diseases is propelling the growth of the market over the years. For instance, in May 2021, U.S. FDA granted Emergency Use Authorization (EUA) for the T-Detect COVID-19 routine T-cell test. Similarly, rising number of research for therapeutic drug discovery and growing competition for FDA approvals among the market players is expected to create a lucrative growth during the forecast period. Government initiatives and funding for research and development in cell-based assays have led to the development of new and advanced assays for various applications. The increasing demand for regenerative medicine has led to the development of cell-based assays for the characterization and quality control of stem cells. The growing focus on personalized medicine has led to the development of cell-based assays for patient-specific drug screening, which is expected to drive the growth of the market. The increasing adoption of cell-based assays in academic research for drug discovery, toxicity testing, and disease modeling is expected to drive the growth of the market.

Recent Development

• For instance, in September 2022, researchers at the Fraunhofer Institute developed Proxidrugs to utilize a cells-based waste disposal system as a potential therapeutic option for infections, cancer, and Alzheimer’s disease.
• For instance, in November 2021, Menarini Silicon Biosystems, launched its CELLSEARCH, a laboratory-developed test to aid the enumeration of multiple myeloma cells using a blood sample.
• For instance, in August 2022, LifeNet Health LifeSciences announced the launch of its new cell-based assay services to aid in drug discovery and development.
• Thermo Fisher Scientific launched the CellInsight NXT HCS platform in 2020. This platform enables researchers to perform automated, high-throughput imaging and analysis of cells for a range of applications, including drug discovery and toxicity testing.
• Molecular Devices launched the SpectraMax i3x microplate reader in 2021. This reader can be used for a range of assays, including cell viability, apoptosis, and protein expression. It offers several detection modes, including absorbance, fluorescence, and luminescence, and can perform kinetic measurements.
• NanoSurface Biomedical launched the NanoCulture plate in 2021. This product enables researchers to create and study 3D cell cultures at the nanoscale level, providing a more physiologically relevant model for drug discovery and toxicity testing.
• NanoCellect Biomedical launched the Tycho Cell Analysis System in 2021. This system can be used for the analysis of single cells, providing high-resolution images and quantitative data on cell size, shape, and phenotype. It can be used for a range of applications, including cell sorting and characterization.

Download Free Sample Report

Market Segmentation

The global cell-based assays market can be segmented by products and services, by application, by end user and by region. Based on products and services, the market can be segmented into Reagents, Assay Kits, Microplates, Probes & Labels, Cell Lines, Others. Based on application, the market can be segmented into Clinical Research, Drug Discovery & Development, Others. Based on end user, the market can be differentiated into Biotechnology & Pharmaceutical Companies, Academic & Research Institutions, Contract Research Organizations. Regionally, North America dominated the market among Asia Pacific, Europe, Middle East & Africa, and South America. Among the different countries, United States dominated the global cell-based assays market on account of growing demand for identification and optimization of novel drug in the country.

Market PlayersCorning, Inc., Bio-Rad Laboratories, Inc., Thermo Fisher Scientific Inc., Danaher Corporation, Lonza Group AG, Promega Corporation, F. Hoffmann-La Roche AG, Merck KGaA, Charles River Laboratories International, Inc., Menarini Silicon Biosystems, Inc. are some of the leading players operating in the Global Cell Based Assays Market.

Report Scope:

In this report, Global Cell Based Assays Market has been segmented into following categories, in addition to the industry trends which have also been detailed below:

• Cell Based AssaysMarket, By Products & Services:

o    Reagents

o    Assay Kits

o    Microplates

o    Probes & Labels

o    Cell Lines

o    Others

• Cell Based AssaysMarket, By Application:

o    Clinical Research

o    Drug Discovery & Development

o    Others

• Cell Based AssaysMarket, By End User:

o    Biotechnology & Pharmaceutical Companies

o    Academic & Research Institutions

o    Contract Research Organizations

• Cell Based AssaysMarket, By Region:
• North America
• United States
• Canada
• Mexico
• Europe
• France
• Germany
• United Kingdom
• Italy
• Spain
• Asia Pacific
• China
• India
• Japan
• South Korea
• Australia
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in Global Cell Based Assays Market.

Available Customizations:

With the given market data, TechSci Research offers customizations according to a company’s specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Global Cell Based Assays Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at [email protected]